BIOPHARMA
By
How Will Lantern Pharma’s PredictBBB.ai Advance with 94% Accuracy Revolutionize CNS Drug Development?
Key Highlights Breakthrough AI Methodology Sets New Industry BenchmarkLantern’s proprietary ensemble of machine learning algorithms—including logistic regression, random…
Can Phare Bio’s AI-Driven Antibiotic Discovery Win Herald a New Era in Combating Antimicrobial Resistance?
Key Highlights Harnessing Generative AI to Revolutionize Antibiotic DiscoveryPhare Bio leverages cutting-edge AI to drastically shorten the traditionally…
Will AbbVie’s $1 Billion Move to Acquire Gilgamesh Pioneer a New Era in Mental Health Drug Development?
Key Highlights Advanced Acquisition Talks Reflect Growth Strategy Amid Sector InterestAbbVie, following over $20 billion in acquisitions since…
Can Viridian Therapeutics’ $70M Collaboration with Kissei Pharmaceutical Accelerate Best-in-Class Treatments for Thyroid Eye Disease in Japan?
Key Highlights Strategic Collaboration Combines Strengths to Advance TED Treatment in JapanViridian Therapeutics partners exclusively with Kissei Pharmaceutical…
Could Lilly’s Olomorasib Breakthrough Designation Reshape the First-Line Treatment Landscape in KRAS G12C-Mutant Lung Cancer?
Key Takeaways Regulatory Milestone Positions Lilly in the KRAS Race The U.S. FDA has granted Breakthrough Therapy designation…
Is Novartis’ $5.2B siRNA Expansion with Argo Biopharma the Next Big Move in Cardiovascular?
Key Takeaways Expanding RNAi Leadership in Cardiovascular and Metabolic Diseases Novartis is reinforcing its strategic focus on cardiovascular…
